Bristol-Myers Squibb Company (FRA:BRM)
Germany
· Delayed Price · Currency is EUR 42.31
+0.07 (0.15%)
Last updated: Jun 5, 2025
FRA:BRM Revenue
Bristol-Myers Squibb Company had revenue of $11.20B USD in the quarter ending March 31, 2025, a decrease of -5.60%. This brings the company's revenue in the last twelve months to $47.64B, up 4.62% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.64B
Revenue Growth
+4.62%
P/S Ratio
1.96
Revenue / Employee
$1.40M
Employees
34,100
Market Cap
86.51B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 35.15B |
| Siemens Aktiengesellschaft | 77.82B |
| Deutsche Telekom AG | 120.25B |
| Allianz SE | 107.35B |
| Rheinmetall AG | 10.48B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
| Siemens Energy AG | 37.44B |
| Deutsche Börse AG | 5.95B |
Bristol-Myers Squibb Company News
- 9 days ago - Why the stock rally fizzled plus, our latest thinking on Goldman and Bristol Myers - CNBC
- 9 days ago - Bristol-Myers Squibb Company (BMY) Bernstein 41st Annual Strategic Decisions Conference (Transcript) - Seeking Alpha
- 10 days ago - Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme - Seeking Alpha
- 10 days ago - Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy - Seeking Alpha
- 10 days ago - Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Wallstreet:Online
- 10 days ago - Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications - Wallstreet:Online
- 10 days ago - Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications - Benzinga
- 11 days ago - Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar - Seeking Alpha